/ EN

Press Releases

JHL Biotech to Provide Manufacturing Services to BeiGene for Immuno-oncology Program

13 Jun 2016

WUHAN, China, June 13, 2016—JHL Biotech, Inc. (TWSE: 6540) (“JHL”) announces that it has entered into a contract manufacturing agreement with BeiGene, Ltd. (NASDAQ: BGNE) (“BeiGene”) for development and IND-enabling production of a new biologic in BeiGene’s immuno-oncology pipeline. This marks the third collaboration between the two companies, with JHL providing services to BeiGene for the development and manufacturing of certain early stage pipeline programs.

“BeiGene is one of the leading biopharmaceutical companies in China, and I have deep admiration for what BeiGene has accomplished so far”, said Racho Jordanov, CEO of JHL. “JHL and BeiGene have a long standing relationship that goes back many years, and it is a privilege to be working with BeiGene again. The JHL team takes pride in our work, and we look forward to collaborating on this new molecular development effort.”

“I’m very pleased to once again have the opportunity to work with JHL,” said John V. Oyler, CEO of BeiGene. “JHL is one of the premier biologics development and manufacturing companies in China and a valued partner to BeiGene. Their team has deep experience and superior quality of service, and I look forward to continuing to build upon our relationship in the many years to come.”

About JHL Biotech

JHL Biotech Inc. (Stock Code: 6540.TWO) is a biopharmaceutical startup founded by a group of industry veterans with deep experience in pharmaceutical development and operations. JHL is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity, and the China Development Industrial Bank. JHL Biotech’s mission is to provide the world with low-cost medicines of exceptional quality. JHL is focused on research and development of new protein-based therapies and biosimilars.

JHL Biotech has two world-class facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards. The JHL Center of Excellence in Taiwan conducts biosimilar pre-clinical and early-clinical phase R&D work. JHL’s facility in Wuhan, China will do commercial-scale manufacturing of biologic therapies. This infrastructure gives JHL the unique ability to manufacture its own product and execute contract orders for select clients.

For more information, please visit www.jhlbiotech.com. JHL Biotech, Inc.

Max Chan
Chief Financial Officer
Phone: +886-936-230-550